Agarwal, Neeraj

Olaparib for Metastatic Castration-Resistant Prostate Cancer

de Bono, J., Mateo, J., Fizazi, K., Saad, F., Shore, N., Sandhu, S., Chi, K. N., Sartor, O., Agarwal, N., Olmos, D., et al. (2020) · New England Journal of Medicine

PARP inhibition in cancer therapyProstate Cancer Treatment and Research

Cited by 2,323

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

Kuderer, N. M., Choueiri, T. K., Shah, D. P., Shyr, Y., Rubinstein, S. M., Rivera, D. R., Shete, S., Hsu, C.-Y., Desai, A., de Lima Lopes, G., et al. (2020) · The Lancet

COVID-19 and healthcare impactsCOVID-19 Clinical Research Studies

Cited by 1,726

Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer

Chi, K. N., Agarwal, N., Bjartell, A., Chung, B. H., Pereira de Santana Gomes, A. J., Given, R., Juárez Soto, Á., Merseburger, A. S., Özgüroğlu, M., Uemura, H., et al. (2019) · New England Journal of Medicine

Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment

Cited by 1,564

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

Kwon, E. D., Drake, C. G., Scher, H. I., Fizazi, K., Bossi, A., van den Eertwegh, A. J. M., Krainer, M., Houede, N., Santos, R., Mahammedi, H., et al. (2014) · The Lancet Oncology

Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment

Cited by 1,511

Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer

Hussain, M., Mateo, J., Fizazi, K., Saad, F., Shore, N., Sandhu, S., Chi, K. N., Sartor, O., Agarwal, N., Olmos, D., et al. (2020) · New England Journal of Medicine

PARP inhibition in cancer therapyProstate Cancer Treatment and Research

Cited by 792

TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors

Tagawa, S. T., Balar, A. V., Petrylak, D. P., Kalebasty, A. R., Loriot, Y., Fléchon, A., Jain, R. K., Agarwal, N., Bupathi, M., Barthelemy, P., et al. (2021) · Journal of Clinical Oncology

Bladder and Urothelial Cancer TreatmentsCancer Immunotherapy and Biomarkers

Cited by 543

Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial

Agarwal, N., Azad, A. A., Carles, J., Fay, A. P., Matsubara, N., Heinrich, D., Szczylik, C., De Giorgi, U., Young Joung, J., Fong, P. C. C., et al. (2023) · The Lancet

Prostate Cancer Treatment and ResearchPARP inhibition in cancer therapy

Cited by 538

NCCN Guidelines Insights: Kidney Cancer, Version 2.2020

Motzer, R. J., Jonasch, E., Michaelson, M. D., Nandagopal, L., Gore, J. L., George, S., Alva, A., Haas, N., Harrison, M. R., Plimack, E. R., et al. (2019) · Journal of the National Comprehensive Cancer Network

Renal cell carcinoma treatmentBladder and Urothelial Cancer Treatments

Cited by 287

Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors

Fizazi, K., Drake, C. G., Beer, T. M., Kwon, E. D., Scher, H. I., Gerritsen, W. R., Bossi, A., den Eertwegh, A. J. M. V., Krainer, M., Houede, N., et al. (2020) · European Urology

Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment

Cited by 185

Levels of fatigue and distress in senior prostate cancer survivors enrolled in a 12-week randomized controlled trial of Qigong

Campo, R. A., Agarwal, N., LaStayo, P. C., O’Connor, K., Pappas, L., Boucher, K. M., Gardner, J., Smith, S., Light, K. C., & Kinney, A. Y. (2014) · Journal of Cancer Survivorship

Cancer survivorship and careComplementary and Alternative Medicine Studies

Cited by 102

Enhancing Triage Efficiency and Accuracy in Emergency Rooms for Patients with Metastatic Prostate Cancer: A Retrospective Analysis of Artificial Intelligence-Assisted Triage Using ChatGPT 4.0

Gebrael, G., Sahu, K. K., Chigarira, B., Tripathi, N., Mathew Thomas, V., Sayegh, N., Maughan, B. L., Agarwal, N., Swami, U., & Li, H. (2023) · Cancers

Artificial Intelligence in Healthcare and EducationEmergency and Acute Care Studies

Cited by 85

Macrophage HIF-1α Is an Independent Prognostic Indicator in Kidney Cancer

Cowman, S. J., Fuja, D. G., Liu, X.-D., Tidwell, R. S. S., Kandula, N., Sirohi, D., Agarwal, A. M., Emerson, L. L., Tripp, S. R., Mohlman, J. S., et al. (2020) · Clinical Cancer Research

Renal cell carcinoma treatmentCancer, Hypoxia, and Metabolism

Cited by 76

ISCA2 inhibition decreases HIF and induces ferroptosis in clear cell renal carcinoma

Green, Y. S., Ferreira dos Santos, M. C., Fuja, D. G., Reichert, E. C., Campos, A. R., Cowman, S. J., Acuña Pilarte, K., Kohan, J., Tripp, S. R., Leibold, E. A., et al. (2022) · Oncogene

Ferroptosis and cancer prognosisCancer, Hypoxia, and Metabolism

Cited by 69

Germline and somatic genomic testing for metastatic prostate cancer: ASCO guideline

Yu, E. Y., Rumble, R. B., Agarwal, N., Cheng, H. H., Eggener, S. E., Bitting, R. L., Beltran, H., Giri, V. N., Spratt, D., Mahal, B., et al. (2025) · Journal of Clinical Oncology

Prostate Cancer Treatment and ResearchCancer Genomics and Diagnostics

Cited by 64

Phase 1 Study of Safety and Preliminary Clinical Activity of JNJ-63898081, a PSMA and CD3 Bispecific Antibody, for Metastatic Castration-Resistant Prostate Cancer

Lim, E. A., Schweizer, M. T., Chi, K. N., Aggarwal, R., Agarwal, N., Gulley, J., Attiyeh, E., Greger, J., Wu, S., Jaiprasart, P., et al. (2023) · Clinical Genitourinary Cancer

Prostate Cancer Treatment and ResearchCancer Immunotherapy and Biomarkers

Cited by 62

Trends and Disparities in Next-Generation Sequencing in Metastatic Prostate and Urothelial Cancers

Hage Chehade, C., Jo, Y., Gebrael, G., Tripathi, N., Sayegh, N., Chigarira, B., Mathew Thomas, V., Galarza Fortuna, G., Narang, A., Campbell, P., et al. (2024) · JAMA Network Open

Prostate Cancer Treatment and ResearchCancer Genomics and Diagnostics

Cited by 44

Seeing the forest for the trees – single-cell atlases link CD8+ T cells and macrophages to disease progression and treatment response in kidney cancer

Koh, M. Y., Sayegh, N., & Agarwal, N. (2021) · Cancer Cell

Cancer Immunotherapy and BiomarkersRenal cell carcinoma treatment

Cited by 28

TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination repair (HRR) gene alterations.

Fizazi, K., Azad, A., Matsubara, N., Carles, J., Fay, A. P., De Giorgi, U., Joung, J. Y., Fong, P. C. C., Voog, E., Jones, R. J., et al. (2023) · Journal of Clinical Oncology

Prostate Cancer Treatment and ResearchPARP inhibition in cancer therapy

Cited by 17

Enfortumab vedotin (EV) as monotherapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of stage I of a phase 2 trial.

Swami, U., Maughan, B. L., Boucher, K. M., Nordblad, B., Lloyd, J., Batten, J., Phunrab, T. K., Quertinmont, J., Kohli, M., Gupta, S., et al. (2024) · Journal of Clinical Oncology

Prostate Cancer Treatment and ResearchLung Cancer Treatments and Mutations

Cited by 9